RegulatorySession 1
Global Regulator Dialogue: Accelerating Access Without Compromising Safety
FDA and the MHRA walk through the programs built to get products to patients faster without compromising safety, including FDA PreCheck, predetermined change control plans, the TAP pilot, Operation TrialBlazer and the MHRA–NICE Integrated Advice Service. Take this intel back as the foundation of your market access and regulatory strategy.
Martha Betz, Ph.D., FDA CDRH · Ashley Boam, FDA CDER · Stephen Maddocks, MHRA
Moderator: Marla Phillips, Pathway for Patient Health
How do top executives prove the value of quality?

Paul Foley
Gilead Sciences

Elaine Shannon
Takeda

Bala Sreenivasan
Merck
Executive leadershipSession 2
Executive Roundtable: The Executive Edge on Advancing Value
The first three numbers each executive checks on Monday morning, why Takeda puts Patient, Trust, Reputation and Business in that order, how tariffs and geopolitics are reshaping supply, and what makes a business case win at budget time.
Paul Foley, Gilead Sciences · Elaine Shannon, Takeda · Bala Sreenivasan, Merck
Moderator: Peter Shearstone, J&J MedTech

Nidia Acevedo
Eli Lilly
Risk managementSession 3Includes live Q&A
One Risk Mindset: How to Achieve True Integration at Every Level
How Eli Lilly aligns risk decisions at every level with its enterprise risk tolerance, why behavior beats bureaucracy, and why, as risk goes up, decisions and support need to come back down.
Nidia Acevedo, SVP Global Quality Compliance, Eli Lilly
Moderator: Ian Hooley, Zimmer Biomet

Nina Alli
Biohacking Village
CybersecuritySession 4Includes live Q&A
Cyber Breach: Take Action!
What hackers at the Biohacking Village are finding in pharma and medtech systems, why authentication is still the front door, a real attack on critical infrastructure, and why Quality needs a seat next to the CISO and IT.
Nina Alli, CEO and Executive Director, Biohacking Village
Moderator: Lacey Harbour, Pathway for Patient Health
Quality systemsSession 5
QMS of the Future: Maximizing Agility
How J&J MedTech is using generative AI to digitize its quality management system: which pain points they tackled first, how they built the business case, how notified bodies validated the work, and what drove adoption.
Peter Shearstone, VP and Chief Quality Officer, J&J MedTech
Moderator: Marcelo Trevino, Illumina
When does AI need validating, and how much?

Charlene Cho
Microsoft AI

Teginder Singh
Google

Taha Jilani
Otsuka

Hari Subramanian
Otsuka
AI & data integritySession 6
Is Your AI Telling the Truth? Validation, Data Integrity and Control
A three-question method for deciding when AI needs validation and how much, why whoever rewrites an AI draft decides who the author is, using AI to audit AI, and why you can't document a change you can't detect.
Charlene Cho, Microsoft AI · Teginder Singh, Google · Taha Jilani and Hari Subramanian, Otsuka
Co-moderators: Lacey Harbour and Marla Phillips
What are Notified Body auditors really looking for?

Melissa Di Buono-Russo
TÜV Rheinland North America

Laura Handy
BSI
Audit & inspectionSession 7
Inside the Risk-Based Audit: A Notified Body's Approach
Notified Body auditors walk through a real example, a patient monitor alarm, from intended use through the risk file, and share what they look for in CAPAs and effectiveness checks, and why your documentation should speak for itself.
Melissa Di Buono-Russo, TÜV Rheinland North America · Laura Handy, BSI
Moderator: Colleen Watson, Thermo Fisher Scientific
Global strategySession 8Includes live Q&A
Global Perspective: The Forces Reshaping Our Industry
What Baxter learned when Hurricane Helene shut its North Cove plant, why the next WHO Director-General matters to your supply chain, and how global regulatory complexity is reshaping what quality must deliver.
Gerard (Jerry) Greco, Former CQO, Baxter · Anil Sawant, Former CQO, Merck
Moderator: Marla Phillips, Pathway for Patient Health